The trademark application RYLMM was filed by Eli Lilly and Company, a U.S. corporation (the "Applicant"). The application was published for oppositions on July 13, 2020, and it was registered by office on October 20, 2020 without any oppositions.
The application was filed in English (Italian was selected as the second language).
Appointment and Replacement of representative of the trademark registration was recorded on November 23, 2020.
Goods And Services
The mark was filed in class 5 with following description of goods:
Pharmaceutical preparations namely, pharmaceutical preparations for the treatment, diagnosis and/or prevention of alopecia, Alzheimer's disease, atopic dermatitis, autoimmune diseases and disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cluster headaches, Crohn's disease, dementia, dermatological diseases and disorders
Pharmaceutical preparations for the treatment, diagnosis and/or prevention of diabetes, dyslipidemia, endocrine diseases and disorders, gastrointestinal diseases and disorders, headaches, heart failure, hypoglycemia, inflammation and inflammatory diseases and disorders
Pharmaceutical preparations for the treatment, diagnosis and/or prevention of inflammatory bowel disease, kidney diseases and disorders, liver diseases and disorders, lupus, mental disorders, metabolic diseases and disorders, migraines, multiple sclerosis, muscle diseases and disorders
Pharmaceutical preparations for the treatment, diagnosis and/or prevention of neurodegenerative diseases and disorders, neurological disorders, obesity, pain, Parkinson's disease, Psoriasis, Psoriatic arthritis, rheumatoid arthritis, Sjogren's syndrome, sleep disorders, spondyloarthropathy and ulcerative colitis
Diagnostic agents and substances for medical purposes
Radiopharmaceutical diagnostic preparations for use in the diagnosis of neurodegenerative diseases and of oncology and of pain